New drugs and combinations for the treatment of soft-tissue sarcoma: a review
Sarcomas are a heterogeneous group of solid tumors arising from either soft tissues or bone, accounting for approximately 1% of all cancers in adults. Management of these diseases has changed little over the past 10 years, with the exception of treatment of gastrointestinal stromal tumors. Reasons f...
Main Authors: | , |
---|---|
Format: | Online |
Language: | English |
Published: |
Dove Medical Press
2012
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514064/ |
id |
pubmed-3514064 |
---|---|
recordtype |
oai_dc |
spelling |
pubmed-35140642012-12-05 New drugs and combinations for the treatment of soft-tissue sarcoma: a review Somaiah, Neeta von Mehren, Margaret Review Sarcomas are a heterogeneous group of solid tumors arising from either soft tissues or bone, accounting for approximately 1% of all cancers in adults. Management of these diseases has changed little over the past 10 years, with the exception of treatment of gastrointestinal stromal tumors. Reasons for this stagnation include multiple histologies commonly grouped together in clinical trials limiting the understanding of benefit of treatment and limited investigation of molecular targeted therapies. More recently, advances in molecular pathogenesis, the advent of novel and targeted therapeutics, and increasing collaborations between sarcoma investigators has helped move the field forward in the right direction. Here, we review the recent data on novel agents tested for the management of adult soft-tissue sarcomas, excluding gastrointestinal stromal tumors. Dove Medical Press 2012-11-23 /pmc/articles/PMC3514064/ /pubmed/23226072 http://dx.doi.org/10.2147/CMAR.S23257 Text en © 2012 Somaiah and von Mehren, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
repository_type |
Open Access Journal |
institution_category |
Foreign Institution |
institution |
US National Center for Biotechnology Information |
building |
NCBI PubMed |
collection |
Online Access |
language |
English |
format |
Online |
author |
Somaiah, Neeta von Mehren, Margaret |
spellingShingle |
Somaiah, Neeta von Mehren, Margaret New drugs and combinations for the treatment of soft-tissue sarcoma: a review |
author_facet |
Somaiah, Neeta von Mehren, Margaret |
author_sort |
Somaiah, Neeta |
title |
New drugs and combinations for the treatment of soft-tissue sarcoma: a review |
title_short |
New drugs and combinations for the treatment of soft-tissue sarcoma: a review |
title_full |
New drugs and combinations for the treatment of soft-tissue sarcoma: a review |
title_fullStr |
New drugs and combinations for the treatment of soft-tissue sarcoma: a review |
title_full_unstemmed |
New drugs and combinations for the treatment of soft-tissue sarcoma: a review |
title_sort |
new drugs and combinations for the treatment of soft-tissue sarcoma: a review |
description |
Sarcomas are a heterogeneous group of solid tumors arising from either soft tissues or bone, accounting for approximately 1% of all cancers in adults. Management of these diseases has changed little over the past 10 years, with the exception of treatment of gastrointestinal stromal tumors. Reasons for this stagnation include multiple histologies commonly grouped together in clinical trials limiting the understanding of benefit of treatment and limited investigation of molecular targeted therapies. More recently, advances in molecular pathogenesis, the advent of novel and targeted therapeutics, and increasing collaborations between sarcoma investigators has helped move the field forward in the right direction. Here, we review the recent data on novel agents tested for the management of adult soft-tissue sarcomas, excluding gastrointestinal stromal tumors. |
publisher |
Dove Medical Press |
publishDate |
2012 |
url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514064/ |
_version_ |
1611937896584970240 |